Published October 2, 2025
| Version v1
Journal article
Open
The role of pharmacists in managing mental health disorders: a review
Authors/Creators
- 1. Medical University "Prof. Dr. Paraskev Stoyanov", Varna, Bulgaria
- 2. UMHAT "St. Marina", Varna, Bulgaria|Medical University "Prof. Paraskev Stoyanov", Varna, Bulgaria
Description
Pharmacists are participants in the treatment and management of mental disorders as integral members of multidisciplinary healthcare teams. Their roles extend beyond dispensing medications to providing counseling, promoting adherence, managing drug interactions, assessing treatment outcomes, and supporting symptom management—all while ensuring empathy and confidentiality. They face challenges such as nonadherence, communication barriers, and public stigma. Pharmacists manage complex drug interactions, particularly those between psychiatric medications and nutritional supplements. In hospitals, clinical pharmacists optimize therapy, monitor treatment effectiveness, and train staff in mental health pharmacotherapy. This article emphasizes the need for specialized training for pharmacists to enhance their mental health care competencies. Countries such as the USA, UK, and Australia have successfully implemented such programs, while Bulgaria is integrating mental health care into pharmaceutical practice, expanding the responsibilities of pharmacists and raising public awareness. These achievements highlight the essential contribution of pharmacists to improving mental health outcomes and addressing related challenges.
Files
PHAR_article_165494.pdf
Files
(862.2 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:568474b7a2d68c10219cc60e44471308
|
728.0 kB | Preview Download |
|
md5:1b31fc4bb860f4e84113e7a402d91b07
|
134.2 kB | Preview Download |
Additional details
References
- American Society of Health-System Pharmacists (ASHP) (2019) ASHP Guidelines on the Pharmacist's Role in Substance Use Prevention and Education. American Journal of Health-System Pharmacy 76(5): 356–367. https://doi.org/10.1093/ajhp/zxy080
- Ashcroft R, Mathers A, Gin A, Lam S, Donnelly C, Brown JB, Kourgiantakis T, Mehta K, Rayner J, Sur D, Adamson K, Kirvan A, Dolovich L (2024) Pharmacists' role and experiences with delivering mental health care within team-based primary care settings during the COVID-19 pandemic. International Journal of Pharmacy Practice 32(2): 156–163. https://doi.org/10.1093/ijpp/riad086
- Babor TF, Caetano R, Casswell S, Edwards G, Giesbrecht N, Graham K, Rossow I(2010) Alcohol: No Ordinary Commodity: Research and Public Policy, 2nd edn (Oxford, 2010; online edn, Oxford Academic, 1 May 2010). https://doi.org/10.1093/acprof:oso/9780199551149.001.0001
- Bhat S, Kroehl ME, Trinkley KE, Chow Z, Heath LJ, Billups SJ, Loeb DF (2018) Evaluation of a Clinical Pharmacist-Led Multidisciplinary Antidepressant Telemonitoring Service in the Primary Care Setting. Population Health Management 21(5): 366–372. https://doi.org/10.1089/pop.2017.0144
- Bingham J, Axon DR, Scovis N, Taylor AM (2018) Evaluating the effectiveness of clinical pharmacy consultations on nutrition, physical activity, and sleep in improving patient-reported psychiatric outcomes for individuals with mental illnesses. Pharmacy (Basel) 7(1): 2. https://doi.org/10.3390/pharmacy7010002
- Bingham J, Silva-Almodóvar A, Lee H, Benson C, Michael R, Azurin CM, Taylor AM (2020) The role of the pharmacist in mental health: An investigation of the impact of pharmacist-led interventions on psychotropic medication adherence in patients with diabetes. Journal of the American Pharmacists Association: JAPhA 60(4): e58–e63. https://doi.org/10.1016/j.japh.2020.01.009
- Brown MT, Bussell JK (2011) Medication adherence: WHO cares? Mayo Clinic Proceedings 86(4): 304–314. https://doi.org/10.4065/mcp.2010.0575
- Capoccia K, Boudreau D, Blough D, Ellsworth A, Clark D, Stevens N, Katon W, Sullivan S (2004) Randomised trial of pharmacist interventions to improve depression care and outcomes in primary care. American Journal of Health-System Pharmacy 61(4): 364–372. https://doi.org/10.1093/ajhp/61.4.364
- Chavez B, Kosirog E (2019) Impact on an integrated psychiatric pharmacy service in a primary care clinic. The Mental Health Clinician 9(4): 269–274. https://doi.org/10.9740/mhc.2019.07.269
- Chen T (2008) Community pharmacy's role in managing mental illness. Australian Journal of Pharmacy 89(1058): 74–76.
- Clayton AH, Croft HA, Handiwala L (2014) Antidepressants and sexual dysfunction: mechanisms and clinical implications. Postgraduate Medicine 126(2): 91–99. https://doi.org/10.3810/pgm.2014.03.2744
- Cochran G, Gordon AJ, Lo-Ciganic W (2017) Prescription opioid misuse: Pharmacists' role in preventing abuse. Journal of the American Pharmacists Association 57(2): S67–S72.e2. https://doi.org/10.1016/j.japh.2017.01.010
- Eaves S, Gonzalvo J, Hamm JA, Williams G, Ott C (2020) The evolving role of the pharmacist for individuals with serious mental illness. Journal of the American Pharmacists Association 60(5): S11-4. https://doi.org/10.1016/j.japh.2020.04.017
- El-Den S, Collins JC, Chen TF, O'Reilly CL (2021) Pharmacists' roles in mental healthcare: Past, present and future. Pharmacy Practice 19(3): 2545. https://doi.org/10.18549/PharmPract.2021.3.2545
- Farag M, Chalmers L, Hoti K, Hughes J (2022) The role of the clinical pharmacist in mental health hospital-in-the-home: A scoping review. Research in Social and Administrative Pharmacy 18(10): 3724–3735. https://doi.org/10.1016/j.sapharm.2022.04.004
- Fergusson D, Doucette S, Glass KC, Shapiro S, Healy D, Hebert P, Hutton B (2005) Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomized controlled trials. BMJ 330(7488): 396. https://doi.org/10.1136/bmj.330.7488.396
- Finley PR, Crismon ML, Rush AJ (2003) Evaluating the impact of pharmacists in mental health: A systematic review. Pharmacotherapy 23(12): 1634–1644. https://doi.org/10.1592/phco.23.15.1634.63502
- Fleischhacker WW, Uchida H (2014) Critical review of antipsychotic polypharmacy in the treatment of schizophrenia, International Journal of Neuropsychopharmacology 17(7): 1083–1093. https://doi.org/10.1017/S1461145712000399
- Foong AL, Grindrod KA, Patel T, Kellar J (2018) Demystifying serotonin syndrome (or serotonin toxicity). Canadian Family Physician 64(10): 720–727.
- Freeman MP, Fava M, Lake J, Trivedi MH, Wisner KL, Mischoulon D (2010) Complementary and alternative medicine in major depressive disorder: the American Psychiatric Association Task Force report. The Journal of Clinical Psychiatry 71(6): 669–681. https://doi.org/10.4088/JCP.10cs05959blu
- Getov I, Kostov E, Lebanova H, Grigorov E (2013) Clinical pharmacy – essence, progress and challenges in practice. Medicinski Pregled 49(3): 30–37.
- Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Carrier J, Khan IA, Edwards DJ, Shah A (2004) In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clinical Pharmacology and Therapeutics 76(5): 428–440. https://doi.org/10.1016/j.clpt.2004.07.007
- Higgins A, Nash M, Lynch AM (2010) Antidepressant-associated sexual dysfunction: impact, effects, and treatment. Drug, Healthcare and Patient Safety 2: 141–150. https://doi.org/10.2147/DHPS.S7634
- International Pharmaceutical Federation (FIP) (2019) Pharmacy's role in harm reduction. https://www.fip.org/file/4325 [Accesed 25.02.2025]
- International Pharmaceutical Federation (FIP) (2020) Development Goals for Pharmacy Education and Workforce. https://www.fip.org/development-goals [Accesed 15.05.2025]
- Izzo AA, Ernst E (2009) Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs 69(13): 1777–1798. https://doi.org/10.2165/11317010-000000000-00000
- Jing E, Straw-Wilson K (2016) Sexual dysfunction in selective serotonin reuptake inhibitors (SSRIs) and potential solutions: A narrative literature review. The Mental Health Clinician 6(4): 191–196. https://doi.org/10.9740/mhc.2016.07.191
- Joel J (2022) A Clinical Pharmacist-Led Study of Drug-Drug Interactions in Patients with Psychiatric Disorders. Journal of Cellular and Molecular Pharmacology 6(4): 130.
- Kamusheva M, Ignatova D, Golda A, Skowron A (2020) The potential role of the pharmacist in supporting patients with depression – A literature-based point of view. Integrated Pharmacy Research and Practice 9: 49–63. https://doi.org/10.2147/IPRP.S239672
- Kane JM, Kishimoto T, Correll CU (2013) Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry 12(3): 216–226. https://doi.org/10.1002/wps.20060
- Karolewicz B, Nowak M, Gawin A, Milejski P, Owczarek A (2020) Identification of the area services provided by a pharmacist in the care of patients with mental health problems: Conditions, possibilities of care providing, and the needs of patients. Acta Poloniae Pharmaceutica – Drug Research 77(5): 281–296. https://doi.org/10.32383/farmpol/125320
- Kelly K, Posternak M, Alpert JE (2008) Toward achieving optimal response: understanding and managing antidepressant side effects. Dialogues in Clinical Neuroscience 10(4): 409–418. https://doi.org/10.31887/DCNS.2008.10.4/kkelly
- Khartabil N, Haghparast P, Al-Chokachi Z, Clemens E (2024) The impact of pharmacists on medication safety in mental health: A narrative review. JACCP: Journal of the American College of Clinical Pharmacy 7(2): 177–189. https://doi.org/10.1002/jac5.1900
- Klang SH, Ben-Amnon Y, Cohen Y, Barak Y (2015) Community pharmacists' support improves antidepressant adherence in the community. International Clinical Psychopharmacology 30(6): 316–319. https://doi.org/10.1097/YIC.0000000000000090
- Kremin Y, Lesyk L, Lesyk R, Levytska O, Khromovyk B (2023) Detailing the ten essential professional roles of the pharmacist to ensure the scope of professional functions. Scientia Pharmaceutica 91(1): 5. https://doi.org/10.3390/scipharm91010005
- Lindson N, Richards-Doran D, Heath L, Hartmann-Boyce J (2023) Motivational interviewing for substance use. Cochrane Database of Systematic Reviews (12): 1–219. https://doi.org/10.1002/14651858.CD008063.pub3
- McMillan SS, Kelly F, Hattingh HL, Fowler JL, Mihala G, Wheeler AJ (2018) The impact of a person-centred community pharmacy mental health medication support service on consumer outcomes. Journal of Mental Health 27(2): 164–173. https://doi.org/10.1080/09638237.2017.1340618
- Medical University of Plovdiv (2020) Curriculum for the specialization "Pharmacist Assistant". https://mu-plovdiv.bg/wp-content/uploads/2020/10/uchebni_programi_spetsialnost_spetsialnost_pomoshtnik_farmacevt.pdf#page=363 [Accesed 01.03.2025]
- Millan MJ, Agid Y, Brüne M, Bullmore ET, Carter CS, Clayton NS, Connor R, Davis S, Deakin B, DeRubeis RJ, Dubois B, Geyer MA, Goodwin GM, Gorwood P, Jay TM, Joëls M, Mansuy IM, Meyer-Lindenberg A, Murphy D, Rolls E, Saletu B, Spedding M, Sweeney J, Whittington M, Young LJ (2012) Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nature Reviews Drug Discovery 11(2): 141–168. https://doi.org/10.1038/nrd3628
- Ministry of Health (2020) National Strategy for the Development of Clinical Pharmacy in Hospital Care; https://old.mh.government.bg/bg/politiki/strategii-i-kontseptsii/strategii/ [Accesed 15.05.2025]
- Ministry of Health (2004–2012) Mental Health Policy 2004–2012 https://www.mh.government.bg/upload/3453/politika-psihichno-zdrave-2004-2012.pdf [Accesed 25.03.2025]
- Moini J, Ross M [Eds] (2016) Fundamentals of Pharmacology for Pharmacy Technicians. 2016 2nd edn. CANGAGE Learning; 20 Channel Center Street, Boston, MA 02210, USA.
- Moore CH, Powell BD, Kyle JA (2018) The role of the community pharmacist in mental health. U.S. Pharmacist 43(11): 13–20. ISSN 01484818, Jobson Publishing Corporation.
- Morrison RL, Stomski NJ, Whitely M (2018) Strategies to support medication adherence in people with serious mental illness: a literature review. Mental Health & Prevention 10: 31–41. https://doi.org/10.1016/j.mhp.2018.02.003
- National Institute of Mental Health [NIMH] (2025) Mental Health Information. https://www.nimh.nih.gov [Accesed 25.01.2025]
- National Institute on Drug Abuse [NIDA] (2023) Medications for substance use disorders. https://nida.nih.gov/ [Accesed 25.03.2025]
- NHS Guideline (2018) NHS Guidelines for the Management of QTc Prolongation in Adults Prescribed Antipsychotics. https://www.england.nhs.uk/north/wp-content/uploads/sites/5/2018/12/QTc-flow-diagram-with-medications-final-Dec-17-A3-with-logos.pdf [Accesed 19.08.2025]
- NHS Guideline (2020) NHS Guideline on drug-induced QT prolongation. https://aaamedicines.org.uk/media/m13hdonk/guideline-on-drug-induced-qt-prolongation.pdf [Accesed 19.08.2025]
- NHS Guideline (2022) NHS Guidelines for the management of serotonin syndrome. https://rightdecisions.scot.nhs.uk/media/1831/management-of-serotonin-syndrome.pdf [Accesed 20.08.2025]
- NHS Guideline (2025) NHS Guidelines for the Management of QTc Prolongation with Psychotropic Medication. https://www.tewv.nhs.uk/wp-content/uploads/2021/11/Psychotropic-Medication-Guidelines-for-the-Management-of-QTc-Prolongation-with-Psychotropic-Medication.pdf [Accesed 19.08.2025]
- NHS Specialist Pharmacy Service (2023) NHS Specialist Pharmacy Service Monitoring a person during and after antidepressant switching https://www.sps.nhs.uk/articles/monitoring-a-person-during-and-after-antidepressant-switching [Accesed 20.08.2025]
- NHS Specialist Pharmacy Service (2024) NHS Specialist Pharmacy Service Planning and agreeing an antidepressant switching strategy. https://www.sps.nhs.uk/articles/planning-and-agreeing-an-antidepressant-switching-strategy [Accesed 20.08.2025]
- NICE (2014) NICE Clinical guideline for Psychosis and schizophrenia in adults: prevention and management. https://www.nice.org.uk/guidance/cg178/chapter/recommendations
- NICE (2022) Guideline. Depression in adults: treatment and management; available at: https://www.nice.org.uk/guidance/ng222/chapter/recommendations [Accesed 21.08.2025]
- O'Reilly CL, Bell JS, Chen TF (2010) Pharmacists' beliefs about treatments and outcomes of mental disorders: a mental health literacy survey. Australian and New Zealand Journal of Psychiatry 44(12): 1089–1096. https://doi.org/10.3109/00048674.2010.512864
- Osterberg L, Blaschke T (2005) Adherence to Medication. New England Journal of Medicine 353(5): 487–497. https://doi.org/10.1056/NEJMra050100
- Panesar K (2016) Barriers to counseling patients with mental health disorders. U.S. Pharmacist 41(11): 30–33. https://www.uspharmacist.com/article/barriers-to-counseling-patients-with-mental-health-disorders#:~:text=Health%20System-Related%20Factors%3A%20The,counseling%20and%20lack%20of%20time.&text=Other%20issues%20include%20the%20lack,of%20the%20patient%27s%20medical%20background [Accesed 09.04.2025]
- Rickles NM, Wertheimer AI, Smith MC (2010) Social and Behavioral Aspects of Pharmaceutical Care (3rd edn.). Sudbury, MA: Jones & Bartlett Learning, 484 pp.
- Rieck M, Kim JA (2014) Managing drug interactions with antidepressants. US Pharmacist 39(11): 30–34.
- Royal Pharmaceutical Society (2018) Mental Health Roundtable Report.
- Rubio-Valera M, Chen TF, O'Reilly CL (2014) New roles for pharmacists in community mental health care: A narrative review. International Journal of Environmental Research and Public Health 11(10): 10967–10990. https://doi.org/10.3390/ijerph111010967
- Sarris J, McIntyre E, Camfield DA (2013) Plant-based medicines for anxiety disorders, part 2: a review of clinical studies with supporting preclinical evidence. CNS Drugs 27(4): 301–319. https://doi.org/10.1007/s40263-013-0059-9
- Shepherd N, Beveridge E, Parker C (2022) Impact of a pharmacist in extended role on an acute mental health ward. Progress in Neurology and Psychiatry 26(3): 27–30. https://doi.org/10.1002/pnp.758
- Soubolsky A, Halpape K (2022) The time is now for mental health care: Evaluating the impact of a clinical pharmacist on an acute mental health unit. The Canadian Journal of Hospital Pharmacy 75(4): 317–325. https://doi.org/10.4212/cjhp.3210
- Spina E, de Leon J (2007) Metabolic drug interactions with newer antipsychotics: A comparative review. Basic & Clinical Pharmacology & Toxicology 100(1): 4–22. https://doi.org/10.1111/j.1742-7843.2007.00017.x
- Syrnyk C, Glass BD (2023) Pharmacist interventions in medication adherence in patients with mental health disorders: A scoping review. Research in Social and Administrative Pharmacy 19(6): 321–329. https://doi.org/10.1016/j.sapharm.2023.05.001
- Tai M, Vu L, Bostwick JR (2014) Antidepressant treatment concerns and recommendations for avoiding adverse events. U.S. Pharmacist, 39(11): 34–36. ISSN 01484818, Jobson Publishing Corporation
- The New York State Medicaid Prescriber Education Program (NYSMPEP) (2024) Metabolic Health as an Essential Consideration When Using Antipsychotic Medications. https://nypep.nysdoh.suny.edu/wp-content/uploads/2024/05/Metabolic-Monitoring-of-Antipsychotic-Medications-NYSMPEP-Article-v5.2024.pdf [Accesed 21.08.2025]
- Vandenbroucke RE, Foulon V, De Vriese C, Van Boxem T, Simoens S (2012) Evaluation of drug-drug interaction software in community and hospital pharmacy. European Journal of Clinical Pharmacology 68(5): 547–555.
- Wakeman SE, Barnett ML (2018) Primary care and the opioid-overdose crisis — Buprenorphine myths and realities. New England Journal of Medicine 379(1): 1–4. https://doi.org/10.1056/NEJMp1802741
- Wijesinghe R (2016) A review of pharmacokinetic and pharmacodynamic interactions with antipsychotics. The Mental Health Clinician 6(1): 21–27. https://doi.org/10.9740/mhc.2016.01.021
- Winstanley EL, Clark AN (2018) Engaging pharmacists to address the opioid crisis: A review of programs. Substance Abuse 39(2): 211–215.
- World Health Organization (1997) The Role of the Pharmacist in the Health Care System – Preparing the Future Pharmacist: Curricular Development. Geneva: WHO. Report No.: WHO/PHARM/97/599. https://iris.who.int/bitstream/handle/10665/63817/WHO_PHARM_97_599.pdf [Accesed 01.04.2025]